^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | APG-1842 (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2664/7-Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors
Published date:
03/09/2022
Excerpt:
Significant antitumor activity of APG-1842 was also confirmed in a panel of 8 KRASG12C-mutated patient-derived xenograft models derived from patient samples of lung, colorectal, and gastric cancers. Collectively, these preclinical results suggest that APG-1842 is a potent, bioavailable, and highly selective KRASG12C inhibitor, laying a foundation for clinical development of this agent for patients with KRASG12C-mutant solid tumors.
